Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ares Commercial Real Estate

Archer-Daniels-Midland Company

FTAI Aviation Ltd

Gaming and Leisure Properties

Philip Morris

Walmart

Dividend stocks come in many flavors although investors may associate them primarily with the energy sector. These seven stocks cross industries.

7 Great Dividend Stocks Outside the Energy Sector

AbbVie Inc (NYSE: ABBV) has landed an option to buy Mitokinin upon completing IND-enabling studies on the latter's lead PINK1 compound for Parkinson's disease. Mitokinin's novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson's disease.

AbbVie To Beef Up Neurology Pipeline With Option To Add Parkinson's Candidate

Berkshire's diversification allowed the company to remain highly profitable, despite the pandemic. The company has ramped up share buybacks in recent quarters, which is highly accretive to EPS growth.

Berkshire: Warren Buffett Does Buybacks, Earnings Remain Strong

ARK Genomic Revolution Multi-Sector ETF

There's a pretty good chance the answer is "yes."

Warren Buffett and Cathie Wood Just Bought This Juicy Dividend Stock. Should You?

AbbVie's respective adjusted diluted EPS and FCF payout ratios of 44.7% and 46.0% strike a great balance between deleveraging and rewarding shareholders with generous dividend increases. Even with COVID headwinds, AbbVie generated 3.3% YoY operational revenue growth and 18.1% YoY adjusted diluted EPS growth in 2020.

AbbVie Remains A Buy

D.R. Horton

Fastenal

Franklin Electric

Global Indemnity

Graco

Healthcare Services Group

Lennar

Progressive

Sturm, Ruger & Company

Safety Insurance

SEI Investments

Skyworks Solutions

T. Rowe Price Group

Travelers

Universal Insurance Hlds

Watsco

These 70 Graham Stocks were screened for revenue, assets, long-term-debt, and EPS growth as of Feb. 25, 2021, based on Graham's established criteria. Of the 70, representing all eleven Morningstar Sectors, 40 pay dividends. Broker targeted top 10 Graham dividend-paying net-gainers ranged 9.08%-26.73% topped by RGR and DHI as of 2/25/21.

New Benjamin Graham List Names, 3 Ideal Dogs For March

Apple

Amazon

Coca-Cola

Altria

PepsiCo

Wells Fargo

Euphoric markets are widening the gap between value and growth investments. Let's take a look at safe stocks to buy and hold forever.

7 Safe Stocks You Can Hold Onto Forever

A. O. Smith

Illinois Tool Works

Lowe's

ProShares S&P 500 Dividend Aristocrats ETF

Roper Technologies

The top 5 fastest-growing dividend aristocrats have grown their dividends at almost double the rate of NOBL. 3 of the top 5 fastest-growing dividend aristocrats may offer double-digit returns over the next 3 years.

3 Of The 5 Fastest-Growing Dividend Aristocrats May Offer Double Digit Returns

Allergan, an AbbVie Inc (NYSE: ABBV), has submitted a marketing application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the application by the end of 2021.

AbbVie's Allergan Files US Application AGN-190584 For Presbyopia

Gilead Sciences

Moderna

Microsoft

NVIDIA

Zoom Video

As leading biotechs focus on coronavirus tests, vaccines and a potential cure, top stocks and the economy try to rebound. Follow the coronavirus news here.

Coronavirus News: Stock Market, Economy Continue Coronavirus Rebound

The FDA has approved AbbVie Inc's (NYSE: ABBV) Humira (adalimumab) to treat moderately to severely active ulcerative colitis in pediatric patients five years and older. Approved dosing for HUMIRA will be determined based on the child's weight.

AbbVie's Humira Gets FDA Approval For Pediatric Ulcerative Colitis

NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In...

HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis

Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields.

2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility

Palantir Technologies

Tesla

Here's what the star investor has done recently.

Cathie Wood Couldn't Stop Buying These 3 Stocks for ARK Invest Last Week

Regeneron Pharmaceuticals

These under-appreciated pharma stocks have the potential to become long-term winners.

2 Best Pharma Stocks to Buy Right Now

Bristol-Myers

Yes -- if you're looking for the same qualities in a stock that the billionaire investor is.

Warren Buffett Just Bought These 2 Dirt-Cheap Stocks. Should You?

Kroger

Merck

GuruFocus is proud to announce that there were three winners of the fourth-quarter Warren Buffett (Trades, Portfolio) contest: Richday101, Chihin and Nicola Guida. Richday101 and Chihin guessed correctly that Buffett (or Ted Weschler, or Todd Combs) purchased AbbVie Inc. (NYSE:ABBV), Merck & Co. Inc. (NYSE:MRK) and Bristol-Myers Squibb Co. (NYSE:BMY).

GuruFocus Announces 3 Winners of 4th-Quarter Warren Buffett Contest

Franklin Resources

Prudential Financial

Prudential Financial, AbbVie, and Franklin Resources currently have the highest dividend yields in the portfolio. Prudential, AbbVie, and Franklin post a 5.7%, 4.8%, and 4.3% dividend rate respectively.

3 Big Yield Opportunities

AbbVie Inc (NYSE: ABBV) announces data from the second Phase 3 study, U-ACCOMPLISH, evaluating upadacitinib in patients with moderate to severe ulcerative colitis. The study met the primary and secondary endpoints.

AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study

NORTH CHICAGO, Ill., Feb. 22, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints in the Phase 3 induction study, U-ACCOMPLISH.1 In the...

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

Exxon Mobil

Investing in these stocks could result in hundreds or thousands of dollars in passive income.

Ready to Supercharge Your Passive Income? 3 Dividend Stocks You Can't Go Wrong With

Evolus

Evolus Inc (NASDAQ: EOLS), AbbVie Inc (NYSE: ABBV), and Medytox announced settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau. It is a prescription medicine injected into muscles and used in adults temporarily to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).

Evolus Shares Surge After Settling Jeuveau Related Litigation With AbbVie, Medytox

News for AbbVie Stock (ABBV)